GleamWall
中文EN

KYNB KYNTRA BIO, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 921299 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY104.5%
TTM net income YoY-108.0%
TTM EPS YoY-108.0%
Revenue 3-yr CAGR-67.5%
Net income 3-yr CAGR—

Margins

Gross margin5.6%
Operating margin-1,089.4%
Net margin-326.0%
FCF margin-913.7%
EBITDA margin-1,089.4%

Returns

ROE—
ROA-18.6%
ROIC (approx.)—
Asset turnover0.06x

Leverage & solvency

Liabilities / assets114.7%
Debt / equity—
Current ratio1.16x
Interest coverage-6.53x

Cash quality & payout

Operating cash flow / net income2.80x
Accruals ratio33.5%
Payout ratio—
Capex / revenue0.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$1.76M-$1.47M$3.74M$1.28M$1.08M$1.35M$2.74M-$123.26M
Cost of revenue$619,000$2,000$4.11M$278,000-$58,000$85,000$252,000-$20.67M
Gross profit$1.14M-$1.48M-$368,000$999,000$1.13M$1.26M$2.49M-$102.59M
R&D expense$8.27M$6.82M$7.57M$7.27M$1.21M$5.87M$9.18M$1.49M
SG&A expense$5.76M$9.27M$5.86M$7.25M$5.29M$7.06M$8.11M-$13.32M
Operating income-$12.87M-$17.57M-$13.82M-$13.51M-$5.41M-$12.05M-$14.92M-$91.66M
Interest expense$1.63M$2.37M$2.43M$2.41M$2.08M$2.01M$2.26M-$6.53M
Pretax income$157,000$11.97M-$15.13M-$14.61M-$13.15M-$13.78M-$16.76M-$8.66M
Income tax$0-$1,000$0$0$0-$92,000$2,000-$52,000
Net income$157,000$11.97M-$15.20M-$14.22M$200.64M-$7.60M$4.64M$17.98M
EBITDA-$12.87M-$17.57M-$13.82M-$13.51M-$5.23M-$11.84M-$14.60M-$91.31M
EPS (basic)0.042.96-3.76—49.61-1.881.15—
EPS (diluted)0.042.96-3.76—49.61-1.881.15—
Weighted avg. shares (diluted)4.05M4.05M4.05M—4.04M4.04M4.04M—
Balance sheet
Cash & equivalents$9.90M$50.64M$37.00M$47.87M$117.97M$23.37M$33.61M$50.48M
Short-term investments$30.39M$40.67M$50.24M$41.11M———$0
Receivables$3.85M$347,000$5.04M$216,000$121,000$136,000$147,000$481,000
Inventory$3.25M$3.38M$3.38M$3.74M$3.86M$3.86M$3.15M$3.15M
Current assets$48.62M$96.83M$101.36M$99.07M$133.42M$162.32M$148.53M$196.51M
PP&E, net———————$0
Total assets$48.85M$101.08M$109.63M$119.59M$137.01M$178.06M$165.21M$214.53M
Current liabilities$41.76M$36.04M$28.11M$29.24M$35.97M$155.90M$73.39M$133.31M
Total liabilities$56.04M$109.22M$118.92M$115.12M$119.53M$359.08M$340.14M$398.16M
Shareholders' equity-$29.19M-$30.14M-$43.80M-$30.04M-$17.03M-$223.00M-$216.90M-$225.60M
Shares outstanding4.05M4.05M4.05M4.05M4.04M4.04M101.04M4.04M
Cash flow statement
Operating cash flow-$12.24M-$3.99M-$13.89M-$18.33M-$1.85M$12.68M$2.72M-$30.47M
Capital expenditure$0$0$0$0$9,000$13,000$16,000$141,000
Free cash flow-$12.24M-$3.99M-$13.89M-$18.33M-$1.86M$12.67M$2.70M-$30.61M
Investing cash flow$14.30M$17.67M$3.02M-$51.71M$87.16M-$13,000-$16,000$1.72M
Financing cash flow-$42.80M-$5,000-$7,000-$14,000-$85.92M-$9,000-$88,000$5,000
Depreciation & amortization$0$0$0$0$183,000$212,000$318,000$342,000
Stock-based compensation$1.01M$984,000$1.15M$1.19M$662,000$1.87M$2.85M$178,000

Free plan shows the latest 8 periods; Pro shows all 51 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.